Summarized by Masters of Longevity from Longevity Technology.
A concise news piece introducing a patent announcement about a dual-gene therapeutic approach for age-related disorders, useful for readers tracking longevity biotech IP and developments.
Key Takeaways
- Longevity.Technology is growing fast; we are open to conversations with prospective partners and investors who share our vision.
- 12,653,907, titled Methods of Treating or Preventing Age-Related Disorders, covering therapeutic methods that combine human telomerase reverse transcriptase (hTERT) and Follistatin-344 (FST).
- The patent was issued by the United States Patent and Trademark Office on June 16, 2026, and BioViva USA Inc.
